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A prospective investigation of interleukin-8
levels in pediatric acute respiratory failure
and acute respiratory distress syndrome
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Mary K. Dahmer1* and for the BALI and RESTORE Study Investigators, Pediatric Acute Lung Injury and Sepsis
Investigators (PALISI) Network
Abstract
Background: The association of plasma interleukin-8 (IL-8), or IL-8 genetic variants, with pediatric acute respiratory
distress syndrome (PARDS) in children with acute respiratory failure at risk for PARDS has not been examined. The
purpose of this study was to examine the association of early and sequential measurement of plasma IL-8 and/or
its genetic variants with development of PARDS and other clinical outcomes in mechanically ventilated children
with acute respiratory failure.
Methods: This was a prospective cohort study of children 2 weeks to 17 years of age with acute airways and/or
parenchymal lung disease done in 22 pediatric intensive care units participating in the multi-center clinical trial,
Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE). Plasma IL-8 levels were measured
within 24 h of consent and 24 and 48 h later. DNA was purified from whole blood, and IL-8 single nucleotide
polymorphisms, rs4073, rs2227306, and rs2227307, were genotyped.
Results: Five hundred forty-nine patients were enrolled; 480 had blood sampling. Plasma IL-8 levels ranged widely
from 4 to 7373 pg/mL. Highest IL-8 levels were observed on the day of intubation with subsequent tapering. Levels
of IL-8 varied significantly across primary diagnoses with the highest levels occurring in patients with sepsis and the
lowest levels in those with asthma. Plasma IL-8 was strongly correlated with oxygenation defect and severity of
illness. IL-8 was consistently higher in PARDS patients compared to those without PARDS; levels were 4–12 fold
higher in non-survivors compared to survivors. On multivariable analysis, IL-8 was independently associated with
death, duration of mechanical ventilation, and PICU length of stay on all days measured, but was not associated
with PARDS development. There was no association between the IL-8 single nucleotide polymorphisms, rs4073,
rs2227306, and rs2227307, and PARDS development or plasma IL-8 level.
Conclusions: When measured sequentially, plasma IL-8 was robustly associated with multiple, relevant clinical
outcomes including mortality, but was not associated with PARDS development. The wide range of plasma IL-8
levels exhibited in this cohort suggests that further study into the heterogeneity of this patient population and its
impact on individual responses to PARDS treatment is warranted.
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Background
Approximately 3% of children admitted to the pediatric in-
tensive care unit are diagnosed with pediatric acute respira-
tory distress syndrome (PARDS) [1], which currently
carries a mortality rate of 17–51% in children [1–4] and
35–60% in adults [5, 6]. The pathogenesis of both adult and
pediatric ARDS (PARDS) involves the release of
pro-inflammatory cytokines and injury to both the lung
vascular endothelium and alveolar epithelium. As damage
progresses, proteins leak into the alveolar space, further
stimulating the influx of neutrophils and macrophages into
the area, propagating the inflammatory response [7, 8]. The
influx of neutrophils is triggered by the increased expres-
sion and release of the chemoattractant, interleukin-8
(IL-8). The expression of IL-8 is stimulated by the classic
pro-inflammatory cytokines tumor necrosis factor (TNF)
and IL-1 which are released early in the inflammatory re-
sponse. IL-8 is produced by multiple cell types including,
but not limited to, monocytes, macrophages, fibroblasts,
and endothelial cells [9]. Plasma IL-8 levels are almost im-
measurable in the healthy child and are specifically elevated
under conditions which trigger inflammation [8, 10–15].
In adults with ARDS, elevated levels of IL-8 in both
plasma and bronchoalveolar lavage fluid have been asso-
ciated with increased risk of death and multiple organ
system failures [16–18]. In pediatrics, initial investiga-
tions indicate that elevations in plasma IL-8 measured at
the start of PARDS correlate with worse clinical out-
comes and mortality [8]. The association of IL-8 with
outcomes in children with acute respiratory failure at
risk for PARDS, or on multiple days after established
PARDS, has not been examined, nor has the association
of genetic variants of IL-8 with PARDS been examined.
We hypothesized that plasma IL-8 or specific IL-8 vari-
ants would be associated with PARDS and with worse
clinical outcomes both in children at risk for PARDS
and in children with PARDS. The objective of this study
was to determine whether plasma IL-8 levels, measured
on sequential days in pediatric patients with acute re-
spiratory failure, can identify children at increased risk
of developing PARDS or correlate with clinically relevant
outcomes in children with acute respiratory failure.
Methods
This study, Genetic Variation and Biomarkers in Chil-
dren with Acute Lung Injury (BALI), was an ancillary
study to the multi-site clinical trial, Randomized Evalu-
ation of Sedation Titration for Respiratory Failure (RE-
STORE; U01 HL086622) [19]. BALI was designed to
examine the association of specific plasma protein and
genetic biomarkers with PARDS in prospectively en-
rolled children with acute respiratory failure. Details of
the study methodology have been published previously
[20]. Twenty-two of the 31 pediatric intensive care units
(PICUs) participating in RESTORE also participated in
this study. The study was approved by the Institutional
Review Boards at all participating sites. Blood samples
were taken within 24 h of consent and again 24 and 48 h
later. Plasma IL-8 was assayed in duplicate by ELISA
(R&D Systems, #D800C). The reported limit of detection
of the assay is 7.5 pg/ml; intra- and inter-assay coeffi-
cients of variations are reported to be 5.8% and 7.7%,
respectively.
The primary analyses examined the association of
plasma or genetic biomarkers with the presence of
PARDS. For plasma IL-8, analyses examining the associ-
ation with the presence of PARDS were done both
across days and on each individual day. PARDS was de-
fined using oxygenation index (OI) or oxygen saturation
index (OSI) as described by the Pediatric Acute Lung In-
jury Consensus Conference [3] except that all patients
defined as having PARDS also had bilateral infiltrates
within 2 days before or 1 day after meeting OI or OSI
criteria for PARDS. These chest radiograph criteria were
applied as RESTORE and BALI were both conceived
when the American European Consensus Conference
(AECC) definition [21] was used to identify PARDS.
Consequently, chest radiograph data only included the
presence or absence of bilateral infiltrates. Individual
chest radiographs were not collected as part of either
study. Secondary analyses examined the association of
biomarkers with oxygenation defect (OI, PaO2/FiO2) and
other relevant clinical outcomes including duration of
mechanical ventilation, PICU length of stay in survivors,
and 90-day in-hospital mortality. Duration of mechanical
ventilation was defined as done in RESTORE [19] with
patients assigned 28 days if they remained intubated or
were transferred or died prior to day 28, therefore mak-
ing this outcome equivalent to ventilator-free days.
Evaluation of the impact of the primary diagnosis associ-
ated with acute respiratory failure was conducted in two
ways. First, diagnostic categories were evaluated based
on categories reported in the parent RESTORE trial
(bronchiolitis, aspiration, sepsis, pneumonia, asthma,
and others). In addition, the primary diagnoses were tricho-
tomized into infectious (bronchiolitis, laryngotracheobron-
chitis, pertussis, pneumonia, sepsis), non-infectious (thoracic
trauma, aspiration, edema, and transfusion-associated), and
indeterminant (asthma, chronic lung disease, acute respira-
tory failure post bone marrow transplantation, pulmonary
hemorrhage, and acute chest syndrome) categories.
Statistics
The statistical analysis was performed using SAS version
9.4. Development of PARDS, death, duration of mechan-
ical ventilation, and length of PICU stay in survivors
were the outcomes examined for association with
plasma IL-8 levels across all days and if significant with
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IL-8 levels on each individual day. Due to the skewed
distribution of plasma IL-8 levels, a natural log trans-
formation was used for the analyses. Basic univariate (in-
cluding frequency distributions or means, medians and
standard deviations, analysis of variance, Wilcoxon
rank-sum tests) and bivariate (including chi-square,
Fisher’s exact, t tests, Pearson correlations, or longitu-
dinal models, as appropriate) analyses of all demo-
graphic measures, clinical measures, and outcomes were
conducted across all study days and on each individual
study day (0, 1, 2, and 3). Comparisons with respect to
these variables used generalized estimating equations
(GEE) to account for correlations within individuals.
Study hypotheses were evaluated using longitudinal
models across days and if significant, with separate
models for each day using logistic regression models for
binary outcomes, Poisson regression models for the dur-
ation of mechanical ventilation, and linear regression for
the length of PICU stay. The results of the bivariate ana-
lyses and forward stepwise linear models were used to
develop the final multivariate models. The potential co-
variates of age, gender, race, ethnicity, prior medical
co-morbidity (including the history of prematurity,
asthma, seizure disorder, neurological disorder, cancer,
or immune deficiency), primary diagnosis associated
with acute respiratory failure, and PRISM III score were
considered for the multivariate models. For the final
models, each outcome was modeled as a function of age,
PRISM III score, diagnosis of sepsis, and IL-8 level, with
study day included when longitudinal models across all
days were evaluated. The diagnosis of sepsis was corre-
lated to a past medical history of cancer and of immune
deficiency; therefore, only sepsis was included in the
final model. All multivariable logistic regression models
of the binary outcomes accounted for individual cluster-
ing using GEE and adjusted for the covariates to assess
the association of IL-8 across all days with outcomes.
Final models for each individual day included IL-8 as a
fixed covariate, whereas when examining IL-8 across all
days, IL-8 was included as a time-varying covariate. The
GEE analysis across all days included only patients with
two (n = 143) or three (n = 208) IL-8 measurements
within the time frame of interest; 73 patients with only
one measurement were not included in the analysis. The
total number of patients included in analyses done on
each day is indicated in the figures, or is shown in table
legends, and includes the 73 patients that were dropped
from the analyses done across all days. We reported
odds ratios with 95% confidence intervals. All statistical
tests were two-tailed, with a significance level of 0.05.
Genotyping and genetic association analysis
DNA was extracted from whole blood using the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI).
Ninety-two percent of the samples (n = 481) had sufficient
DNA for genotyping which was done using a custom Illu-
mina Golden gate panel which included the three IL-8
SNPs of interest, rs4073, rs2227306, and rs2227307. SNP
call rates were 100%, and genotypes did not deviate from
Hardy-Weinberg equilibrium. Genotyping was done
blinded to the clinical status of individuals. The associ-
ation of these genetic variants with PARDS was examined
as described previously [20]. Briefly, the cohort was strati-
fied by race and ethnicity into three major subgroups,
non-Hispanic Caucasians, Hispanic Caucasians, and Afri-
can Americans (52%, 20%, and 17% of the cohort, respect-
ively). Association of IL-8 SNPs with PARDS within each
group was examined, and then, results of the individual
subgroups were combined and examined by meta-analysis
using the program METAL [22].
Results
Five hundred forty-nine patients were enrolled in the
study with 480 having plasma samples. Clinical charac-
teristics of the entire BALI cohort as well as those with
and without PARDS have been described previously [20].
In brief, the patients enrolled in BALI were of mixed
race and ethnicity with the major groups being
non-Hispanic White (52%, n = 287), Hispanic White
(20%, n = 113), and African American (17%, n = 92). The
most frequent primary diagnoses associated with acute
respiratory failure were pneumonia (37%, n = 203), bron-
chiolitis (20%, n = 107), and acute respiratory failure re-
lated to sepsis (19%, n = 104). Prior medical
co-morbidities included history of asthma (16%, n = 89),
prematurity (13%, n = 72), seizure disorder (10%, n = 56),
neurological disorder (8% n = 45), cancer (7%, n = 37),
and immune deficiency (2%, n = 13). There were no sta-
tistically significant differences in any of the clinical
characteristics of the patients that consented for the
BALI study who did, or did not, have plasma IL-8 or
IL-8 genetic variants tested. Mortality in the BALI co-
hort was 9%, with a median duration of mechanical ven-
tilation of 7.1 days (IQR, 4.0–13.6) and a median PICU
length of stay in survivors of 10.6 days (IQR, 6.6–18.4).
Plasma IL-8 levels were highest on the day of intub-
ation (day 0) and tapered over the days to follow with a
statistically significant difference in median values across
the indicated days (p < 0.001, Table 1). There was no as-
sociation between plasma IL-8 level and age or gender
(data not shown). IL-8 was significantly elevated in those
with a past medical history of cancer (p < 0.05 on each
day) or immune deficiency (p < 0.05 on days 1, 2, 3) as
described in Additional file 1. IL-8 was also significantly
higher in children with a primary diagnosis of sepsis
(Additional file 1: Figure S1). The frequency of a primary
diagnosis of sepsis was 38% and 41% in those with a his-
tory of immune deficiency or cancer, respectively.
Flori et al. Critical Care          (2019) 23:128 Page 3 of 8
Plasma IL-8 and PARDS development
Of the 549 patients enrolled in BALI, 69% (n = 378) de-
veloped PARDS. Within the PARDS cohort, 83% met the
diagnosis for PARDS at the time of intubation (day 0)
and 94% by day 1. Plasma IL-8 levels were higher in chil-
dren with PARDS compared to those children without
PARDS on all days measured, but when examining
each day, achieved statistical significance only on day
2 (p = 0.02 on day 2, Fig. 1a). Multivariable analyses
adjusted for age, PRISM III, and sepsis diagnosis
demonstrated that plasma IL-8 was not independently
associated with PARDS across all days or on any spe-
cific day (Additional file 1: Table S3).
Analyses of plasma IL-8 and relevant clinical outcomes
On bivariate analysis of this cohort of children with
acute respiratory failure, plasma IL-8 was significantly
higher in non-survivors on each day measured (Fig. 1b,
p < 0.05) with median IL-8 levels 4–12 fold higher in
non-survivors than survivors. As IL-8 has been reported
to be associated with death in children with PARDS, the
cohort was stratified by PARDS to examine whether
PARDS patients were responsible for the higher IL-8
levels observed in non-survivors. As shown in Fig. 2a,
the levels of IL-8 were significantly higher in survivors
with PARDS compared to survivors without PARDS;
however, the levels of IL-8 were not significantly differ-
ent in non-survivors with and without PARDS (Fig. 2b)
but are higher than those seen in survivors with or with-
out PARDS (Fig. 2b vs a) suggesting that IL-8 is associ-
ated with death in patients with acute respiratory failure
independent of whether the child has PARDS. On multi-
variate analysis with adjustment for severity of illness
(PRISM III), age, and sepsis diagnosis, plasma IL-8 was
independently associated with death on days 1, 2, and 3
(Table 2). When PARDS was added to the model, IL-8
was still independently associated with death (Add-
itional file 1: Table S4) again suggesting that IL-8 is asso-
ciated with death both in the whole cohort and in
patients without PARDS.
Bivariate analysis also indicated that plasma IL-8 was
significantly correlated with duration of mechanical
ventilation on each day measured and with PICU length
of stay on days 1, 2, and 3 (Additional file 1: Table S5).
When duration of mechanical ventilation was dichoto-
mized into 7 or more ventilator days versus fewer than
7 days (median duration of mechanical ventilation was
7.1 days, IQR, 4.0–13.6), plasma IL-8 was significantly
higher in patients with a duration of mechanical ventila-
tion ≥ 7 days on each day measured (p < 0.01, Fig. 3a).
Using 14 days to dichotomize PICU length of stay (me-
dian PICU length of stay was 10.6 days, IQR, 6.6–18.4),
IL-8 was significantly elevated on each day measured in
those patients requiring a prolonged PICU stay (14 or
more days vs fewer than 14 days, p < 0.01 on each day,
Fig. 3b). Using Poisson regression and controlling for
Table 1 Plasma interleukin-8 levels decrease over time
Day N Mean (SD) Median (range)
0 57 759 (1797) 54 (4, 7373)
1 239 344 (1035) 44 (0, 6900)
2 362 252 (872) 39 (0, 8162)
3 325 221 (822) 37 (0, 7706)
IL-8 levels are shown as picogram per milliliter. Day 0 is the day of intubation.
The n is the number of plasma samples analyzed. Plasma IL-8 levels were log
transformed for analysis due to skewness. Medians are significantly different
across days, p < 0.001 using generalizing estimating equations to account for
correlations within individuals
Fig. 1 Plasma interleukin-8 is higher in children with pediatric acute
respiratory distress syndrome and in non-survivors. a Comparison of
plasma IL-8 in children with or without PARDS. The group with
PARDS included children meeting the criteria for PARDS on the
indicated day or any previous day. Plasma IL-8 was significantly
higher in patients with PARDS across all days (p < 0.0001 using GEE
methods as described in the “Methods” section), but when
examining each day only achieved significance on day 2 (p = 0.02). b
Comparison of plasma IL-8 in children who died or survived. IL-8 is
significantly higher in non-survivors on each day (p < 0.05). Day 0 is
the day of intubation. The number inside each bar indicates the
number of plasma samples analyzed from the indicated days. IL-8
interleukin-8, PARDS pediatric acute respiratory distress syndrome
Flori et al. Critical Care          (2019) 23:128 Page 4 of 8
age, severity of illness, and sepsis diagnosis, plasma IL-8
was independently associated with prolonged duration of
mechanical ventilation on each day measured (p ≤ 0.01 on
each day). Finally, plasma IL-8 was associated with pro-
longed PICU length of stay in survivors on each day mea-
sured when adjusted for age and severity of illness and
was also associated with longer length of stay on days 0
(p = 0.01), 2 (p = 0.02), and 3 (p = 0.03) when sepsis
diagnosis was also added to the model (data not shown).
Genetic association studies for IL-8
Three IL-8 SNPs previously reported to be associated with
severity in cystic fibrosis (rs4073, rs2227306, rs2227307)
or with the length of mechanical ventilation in adults with
ARDS (rs4073) were examined for association with
PARDS. The cohort was stratified into non-Hispanic Cau-
casians, Hispanic Caucasians, and African Americans for
analyses which were done with adjustment for population
structure (as described under the “Methods” section).
None of the variants examined showed a significant asso-
ciation with PARDS within any of the subgroups or when
the three subgroups were combined in a meta-analysis
(n = 412). In addition, these variants were not associ-
ated with plasma levels of IL-8.
Discussion
Identification of children within the at-risk population
with a higher likelihood of developing PARDS using ei-
ther specific biomarker levels and/or specific genetic
variations provides a unique insight into PARDS patho-
genesis and may identify novel therapeutic targets allow-
ing future studies to stratify patients so that they might
benefit from targeted therapies. This is the first study in
children examining whether IL-8 is associated with the
development of PARDS. Plasma IL-8 is significantly ele-
vated in pediatric acute respiratory failure and was even
higher in those who develop PARDS; however, multivari-
able analysis adjusting for relevant covariates indicates
that plasma IL-8 is not independently associated with
PARDS.
Our data indicate a very strong association of elevated
IL-8 levels with mortality in this cohort of children with
acute respiratory failure independent of whether the
child had PARDS. IL-8 levels were not significantly dif-
ferent in non-survivors with or without PARDS. Plasma
IL-8 levels in non-survivors are 4–12 fold higher than in
Fig. 2 Comparison of plasma interleukin-8 levels in survivors and
non-survivors with or without pediatric acute respiratory distress
syndrome. a Comparison of plasma IL-8 in survivors with acute
respiratory failure with or without PARDS. IL-8 is significantly higher
in survivors with PARDS on each day (p < 0.05). b Comparison of
plasma IL-8 in non-survivors with acute respiratory failure with or
without PARDS. In non-survivors, IL-8 levels are not significantly
different in children with or without PARDS. Day 0 is the day of
intubation. The number inside each bar indicates the number of
plasma samples analyzed from the indicated days. IL-8 interleukin-8,
PARDS pediatric acute respiratory distress syndrome
Table 2 Multivariable analysis of association of interleukin-8
with death
Day Variable Odds ratio 95% Confidence interval pa
0 IL-8 2.05 0.56–7.46 0.28
Age 1.00 0.83–1.20 0.99
PRISM III 0.96 0.68–1.31 0.73
Sepsis 1.79 0.27–12.1 0.55
1 IL-8 2.33 1.51–3.60 < 0.001
Age 1.14 1.04–1.25 0.007
PRISM III 0.97 0.88–1.06 0.50
Sepsis 0.76 0.20–2.99 0.70
2 IL-8 1.90 1.39–2.60 < 0.001
Age 1.13 1.06–1.22 < 0.001
PRISM III 1.00 0.93–1.08 0.96
Sepsis 1.09 0.38–3.13 0.88
3 IL-8 2.19 1.48–3.24 < 0.001
Age 1.14 1.06–1.22 < 0.001
PRISM III 0.98 0.91–1.06 0.58
Sepsis 0.87 0.24–3.11 0.83
ap value using a multivariable logistic regression model with adjustment for
covariates. The n for days 0–3 is 57, 239, 362, and 325, respectively. Day 0 is
the day of intubation. IL-8 interleukin-8, PRISM pediatric risk of mortality
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survivors, and this elevation is present for several days
after onset of acute respiratory failure. Further, the associ-
ation of IL-8 remained independently associated with
death even after adjusting for many key covariates: sever-
ity of underlying disease (PRISM III), sepsis diagnosis, de-
velopment of PARDS, and others. Plasma IL-8 elevation
was also strongly associated with prolonged mechanical
ventilation, PICU length of stay, and degree of pulmonary
morbidity (as measured by oxygenation defect).
Persistent elevation of IL-8 has been reported in adults
with ARDS and also appears to be related to the differ-
ential impact of ventilator strategy or steroid responsive-
ness in randomized controlled trials of adult ARDS
patients [23–25]. To date, pediatric studies have largely
focused on IL-8 elevations at the onset of disease [8, 26].
The persistence of inflammation after the onset of
pediatric acute respiratory failure in general, and in
PARDS specifically, offers a unique opportunity to deter-
mine whether measuring plasma IL-8 over time can be
used as an indicator of therapeutic effectiveness and/or
disease progression. If so, real-time IL-8 measurement
to guide management strategies in randomized clinical
trials, as well as routine clinical practice, appears prom-
ising if technological advances allowing the measure-
ment of cytokines in real-time were available.
IL-8 levels were highly variable, especially on the day
of intubation (day 0) where levels ranged from 4 to
7373 pg/ml. This degree of variability may have pro-
found implications for future therapeutic trials targeting
the inflammatory cascade in either pediatric respiratory
failure and/or PARDS, particularly since elevated IL-8 is
one of the biomarkers shown to be able to distinguish
between the hyperinflammatory and hypoinflammatory
subphenotypes in adults ARDS [17, 27, 28]. The ob-
served degree of variability in IL-8 levels together with
adult data strongly suggest the need for future studies to
determine whether subphenotypes are also present in
PARDS patients and whether subphenotypes differ be-
tween children and adults.
Although age does impact the development of the im-
mune system and levels of cytokines have been reported
to vary with age, in this cohort of children with acute re-
spiratory failure and/or PARDS, plasma IL-8 was inde-
pendent of age. Indeed, age was not associated with
plasma IL-8 levels on any day measured. This lack of an
association of age with IL-8 levels may be because these
children are critically ill and in the midst of a very
marked inflammatory response and because of the high
degree of variability. The lack of an impact of age on the
association of IL-8 levels with these outcome measures
underscores important similarities between the inflam-
matory pathophysiology exhibited in ARDS in adult and
pediatric patients. Our data support the inclusion of
both adult and pediatric patients into future trial design
aimed at impacting the inflammatory cascades during
early ARDS. However, it remains imperative for any bio-
logical marker which will potentially be used for bedside
risk stratification for clinical or research purposes to be
tested for associations with age and to be evaluated in
both adults and children.
Our study has some limitations. The definition of
PARDS was changed during the study enrollment
period. For the analysis, PARDS was defined using the
more recent PALICC criteria. However, the parent RE-
STORE trial and the BALI study were designed using
AECC criteria to diagnose ARDS; consequently, chest
radiograph interpretation was limited to the presence or
absence of new bilateral infiltrates on each study day.
Lastly, while the majority of patients met the criteria for
PARDS on the day of intubation (day 0), only 16% of
Fig. 3 Plasma interleukin-8 is higher in children with a longer
duration of mechanical ventilation or length of stay. a Comparison
of plasma IL-8 in children with acute respiratory failure who were
mechanically ventilated for ≤ 7 days to those mechanically
ventilated for > 7 days; p < 0.01 on each day. b Comparison of
plasma IL-8 in children with acute respiratory failure who were in
the PICU for ≤ 14 days to those in the PICU for > 14 days; p < 0.01
on each day. Day 0 is the day of intubation. The number inside each
bar indicates the number of plasma samples analyzed from the
indicated days. IL-8 interleukin-8, LOS length of stay in the PICU, MV
mechanical ventilation, PICU pediatric intensive care unit
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patients had blood drawn for plasma biomarkers on day
0. This is noteworthy as it limited our ability to assess
whether plasma IL-8 was higher before the onset of
PARDS in patients who went on to develop PARDS. As
a result, we were unable to determine whether IL-8
levels are significantly higher in those who do not meet
the criteria for PARDS but are destined to develop
PARDS subsequently.
Conclusions
In conclusion, plasma IL-8 is remarkably elevated over
several days after the onset of acute respiratory failure and
PARDS. These elevations are robust and are independ-
ently associated with multiple relevant clinical outcomes,
most importantly death, but are not independently associ-
ated with PARDS. The wide range of plasma IL-8 seen in
our investigation suggests the potential existence of sub-
phenotypes in children with PARDS which should be in-
vestigated further as subphenotypes can significantly
impact future therapeutic trial design. Additional investi-
gation is warranted to determine the utility of serial IL-8
measurement in corroborating disease progression and/or
treatment effectiveness in pediatric acute respiratory fail-
ure and PARDS.
Additional file
Additional file 1: Supplementary tables and figures for a prospective
investigation of interleukin-8 levels in pediatric acute respiratory failure
and acute respiratory distress syndrome. Supplementary tables (S1–S5)
and figures (S1–S2) are found in the additional file. (DOCX 273 kb)
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